**Additional file 3: Table S1 – Overview of associations between volumetric breast density measures (measured with Volpara) and breast cancer risk.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Study design & sample size**(cases/ non cases) | **VDG** OR/HR (95% CI) | **PDV**OR/HR (95% CI) (per SD increase) | **DV**OR/HR (95% CI) (per SD increase) | Adjusted for: |
| Wanders et al. (current study) | Prospective cohort (523/52,814) | VDG 4 vs VDG 1: 3.14 (2.17 ; 4.55)VDG 4 vs VDG2:1.76 (1.32 ; 2.37) | 1.36 (1.25 ; 1.48) | 1.45 (1.32 ; 1.60) | Age, DVadditionally adjusted for NDV |
| Park et al. (2014)[37] | Case-control(677/1,307) | VDG 4 vs VDG 1+2: 3.07 (1.89 ; 4.99) | NA | NA | Age, BMI, parity, postmenopausal HRT use (postmenpausal women only) |
| Eng et al. (2014)[15] | Case-control(414/685) | NA | 1.75 (1.44 ; 2.11) | 1.38 (1.18 ; 1.61) | Age, BMI, menopausal status, parity |
| Brand et al. (2014)[16] | Prospective cohort(206/40,896) | NA | 1.46 (1.22 ; 1.76) | 1.30 (1.12 ; 1.51) | Age, BMI, menopausal status, parity, age at first birth, HRT status, benignbreast disease, family history of BC |
| Brandt et al. (2015)[17] | Case-control (1,911/4,170) | VDG 4 vs VDG 2: 1.82 (1.49 ; 2.21) | 1.47 (1.36 ; 1.60) | 1.31 (1.23 ; 1.40) | Age, BMI  |
| Jeffers et al. (2016)[18] | Case-control(125/274) | VDG 4 vs VDG 2:2.05 (0.90 ; 4.64) | 1.54 (1.12 ; 2.10) | 1.41 (1.11 ; 1,80) | BMI, menopausal status, parity (matched on age and race) |

 VDG: Volpara Density Grades, PDV: Percent Dense Volume, DV: Dense Volume, NDV: Nondense Volume, SD: Standard Deviation, BMI: Body Mass Index, HRT: Hormone Replacement Therapy, BC: Breast Cancer.